The Role of PCSK9 Inhibitors in Managing Patients With Familial Hypercholesterolemia

http://academiccme.com/wp-content/uploads/2017/03/FH-125-x-125-copy.jpg

Course Information

Therapautic Area: Cardiology
Format(s): Webcast, Downloadable Transcript
Credit(s): 1.00 AMA PRA Category 1 Credit(s)™
Activity Dates: March 9, 2017 - March 8, 2018

 

Program Overview

This CME activity will focus on the management of patients with familial hypercholesterolemia and the role of PCSK9 inhibitors in this therapeutic area. Expert faculty will review the science of PCSK9, the updated standards of care for the diagnosis, and FH scoring and management of patients with familial hypercholesterolemia. Clinical trial data of PCSK9 inhibitors for the treatment of familial hypercholesterolemia, including long-term efficacy and safety data, will be analyzed. The faculty will guide physicians on how to implement a multidisciplinary approach to optimally manage patient-specific disease to improve outcomes for patients with familial hypercholesterolemia. Upon completing this activity, physicians will gain knowledge on the most up-to-date care for this cohort of patients.

Target Audience

Cardiologists, internal medicine, primary care physicians, and other healthcare professionals responsible for the diagnosis, treatment or management of familial hypercholesterolemia

Learning Objectives

  1. Review PCSK9 science and updated standards of care for the diagnosis, FH scoring, and management patients and their families with familial hypercholesterolemia
  2. Analyze clinical trial data of PCSK9 inhibitors for the treatment of familial hypercholesterolemia, including long-term efficacy and safety data.
  3. Implement a multidisciplinary approach to optimally manage patient-specific disease to improve outcomes for patients with familial hypercholesterolemia.

Faculty

CannonChristopher P. Cannon
Professor of Medicine
Harvard Medical School
Executive Director of Cardiometabolic Trials
Baim Institute for Clinical Research
Brigham and Women’s Hospital
Boston, Massachusetts

 

Blaha

Michael J. Blaha, MD
Assistant Professor of Medicine
Johns Hopkins School of Medicine
Director of Clinical Research
Ciccarone Center for the Prevention of Heart Disease
Baltimore, Maryland

 

Moriarty

Patrick M. Moriarty, MD
Professor of Medicine
University of Kansas
Director of Clinical Pharmacology and
The Atherosclerosis / Lipoprotein-apheresis Center
Kansas City, Kansas

 

 

UnderbergJames A. Underberg, MD
Clinical Assistant Professor of Medicine
NYU School of Medicine
NYU Center for Prevention of Cardiovascular Disease
Director Bellevue Hospital Lipid Clinic
President-Elect National Lipid Association
New York, New York

 

 

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

 

 Christopher P. Cannon, MD

 

Consultant/Advisor: Alnylam; Amgen, Inc.; Arisaph Pharmaceuticals, Inc.; Boehringer Ingelheim; Bristol-Myers Squibb Company; Eli Lilly and Company; GlaxoSmithKline plc.; Kowa Pharmaceuticals America, Inc.; LipoMedix; Merck & Co., Inc.; Pfizer Inc.;  Regeneron Pharmaceuticals, Inc.; Sanofi; Takeda Pharmaceuticals U.S.A., Inc.

Grant/Research Support: Arisaph Pharmaceuticals, Inc.; AstraZeneca; Boehringer Ingelheim;  Bristol-Myers Squibb Company; GlaxoSmithKline plc.; Janssen Pharmaceuticals, Inc.; Merck & Co., Inc.; Takeda Pharmaceuticals U.S.A., Inc.

Michael J. Blaha, MD

 

Consultant/Advisor: Amgen, Inc.; MedImmune; Novartis Pharmaceutical Corporation

Grant/Research Support: American Heart Association, Inc.; Amgen, Inc.; U.S. Food and Drug Administration

 

 Patrick M. Moriarty, MD

 

Consultant/Advisor: Cymabay Therapeutics

Grant/Research Support: Amgen, Inc.; AstraZeneca Pharmaceuticals LP; Genzyme Corporation; Regeneron Pharmaceuticals, Inc.; Sanofi

Speaker’s Bureau: Aegerion Pharmaceuticals, Inc.; Amgen, Inc.

 

 

 

 

James A. Underberg, MD

 

Consultant/Advisor: Aegerion Pharmaceuticals Inc.; Akcea Therapeutics; Amarin Corp.; Amgen, Inc.; Invitae Corporation; National Lipid Association.; Recombine;

Grant/Research Support: Pfizer Inc.; Aegerion Pharmaceuticals Inc.

Speaker’s Bureau: Alexion Pharmaceuticals, Inc.; Amgen Inc.; AstraZeneca; Genzyme Corporation; Merck & Co., Inc.; Regeneron Pharmaceuticals, Inc.; Sanofi; True Health Diagnostics

 

Planners, Managers, Reviewers

Timothy Hayes, MD, PhD; Emma Gilmartin; Nicole Brestowski; Chelsey Benedek and Megan Gentile hereby state that they or their spouse/life partner do not have any financial relationships to products or devices with any commercial interests related to the content of this activity of any amount during the past 12 months.

Accreditation Statement

AcademicCME is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement

AcademicCME designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Financial Support

This activity has been supported by an independent educational grant from Amgen Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Amgen Inc. do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Method of Participation

In order to claim credit, participants must complete the following:

  1. Read the learning objectives, accreditation information and faculty disclosures at the beginning of this activity.
  2. Complete the Pre-Activity Questions
  3. Read or Review the activity content.
  4. Complete the Post-Activity Test Questions and Evaluation.
  5. Physicians who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a CME Certificate.
  6. All other participants who receive a grade of 70% or better on the Post-Activity Test Questions and who complete the Evaluation will receive a Certificate of Participation.

CME Inquiries/Special Needs

For all CME inquiries or special needs, please contact admin@academiccme.com.

BUTTON


Provided by AcademicCME AcademicCME Logo

This CME activity has been supported by an independent educational grant from Amgen Inc.